🔗 Permalink

Inventor profile of:

Thomas Muster

City:

Vienna

Country:

Austria

Published Applications:

Last publication date:

2023-12-28

Top Assignees for applications by Thomas Muster

The entities that hold a legal rights for patent applications filed by inventor Muster Thomas:

AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG 10 Vienna, Austria
BAXTER HEALTHCARE S.A. 5 Glattpark (Opfikon), Switzerland
Mount Sinai School of Medicine 2 New York, NY United States
BLUE SKY VACCINES GMBH 2 Vienna, Austria
VIVALDI BIOSCIENCES INC. 2 Fort Collins, CO United States
MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY 2 NEW YORK, NY United States
Icahn School of Medicine at Mount Sinai 2 New York, NY United States
AVIR Green Hills Biotechnology Research Development Trade AG 2 Wien, Austria
AVIR GREEN BIOTECHNOLOGY RESEARCH DEVELOPMENT TRAD 1 Vienna, Austria
Avir Green Hills Biotechnology Research Devlopment Trade AG 1 Vienna, Austria
BLUESKY IMMUNOTHERAPIES GMBH 1 Vienna, Australia
Baxalta GmbH 1 Opfikon, Switzerland
RATIER FIGEAC 1 46100 FIGEAC, France
BAXTER HEALTHCARE S.A. 1 Opfikon, Switzerland
AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMEN 1 WIEN, Austria
AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH AG 1 Vienna, Austria
Nanotherapeutics, Inc. 1 Alachua, FL United States
BIA SEPARATIONS D.O.O. 1 Ljubljana, Slovenia

Recent patent applications by Muster Thomas

Thomas Muster from Vienna, AT has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2023-12-28

US20230414745A1

Human necessities

INFLUENZA VIRUS ENCODING A TRUNCATED NS1 PROTEIN AND A SARS-COV RECEPTOR BINDING DOMAIN

#2 | 2022-12-22

US20220401549A1

Human necessities

NOVEL PRIME-BOOST INFLUENZA VACCINE

#3 | 2022-05-26

US20220160863A1

Human necessities

HIGH GROWTH INFLUENZA VIRUS

#4 | 2019-01-31

US20190032084A1

Chemistry; metallurgy

Influenza virus vector for virotherapy

#5 | 2018-01-18

US20180016560A1

Chemistry; metallurgy

NOVEL INFLUENZA VIRUS

#6 | 2016-09-15

US20160264996A1

Chemistry; metallurgy

Influenza virus vector for virotherapy

#7 | 2016-01-07

US20160002606A1

Chemistry; metallurgy

Method for influenza virus purification

#8 | 2014-11-20

US20140341948A1

Human necessities

Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals

#9 | 2014-02-13

US20140045245A1

Chemistry; metallurgy

Replication deficient influenza virus for the expression of heterologous sequences

#10 | 2013-07-18

US20130183740A1

Chemistry; metallurgy

NOVEL METHOD FOR GENERATION OF RNA VIRUS

#11 | 2012-10-11

US20120258134A1

Human necessities

Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals

#12 | 2012-09-20

US20120237527A1

Chemistry; metallurgy

Polynucleotide Fragments of an Infectious Human Endogenous Retrovirus

#13 | 2012-06-28

US20120164175A1

Chemistry; metallurgy

Influenza virus

#14 | 2011-11-03

US20110268764A1

Human necessities

IMMUNE RESPONSE INDUCING PREPARATIONS

#15 | 2011-10-27

US20110262481A1

Chemistry; metallurgy

High growth reassortant influenza A virus

#16 | 2011-10-13

US20110250587A1

Human necessities

Method for generation of RNA virus

#17 | 2010-11-11

US20100285509A1

Human necessities

Melanoma-Associated Endogenous Retrovirus (MERV) Derived Peptide Sequences And Their Therapeutic/Diagnostic Use

#18 | 2010-09-16

US20100233785A1

Human necessities

NOVEL METHODS AND INTERFERON DEFICIENT SUBSTRATES FOR THE PROPAGATION OF VIRUSES

#19 | 2010-07-22

US20100184191A1

Human necessities

Method for generation of RNA virus

#20 | 2010-06-24

US20100158944A1

Chemistry; metallurgy

Method for influenza virus protection

#21 | 2010-06-24

US20100158942A1

Human necessities

ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS

#22 | 2010-06-03

US20100136518A1

Chemistry; metallurgy

Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein

#23 | 2010-06-03

US20100136052A1

Chemistry; metallurgy

REPLICATION DEFICIENT INFLUENZA VIRUS FOR THE EXPRESSION OF HETEROLOGOUS SEQUENCES

#24 | 2010-05-27

US20100129399A1

Chemistry; metallurgy

LINEAR EXPRESSION CONSTRUCTS FOR PRODUCTION OF INFLUENZA VIRUS PARTICLES

#25 | 2009-09-15

US10713732

Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals

#26 | 2009-07-16

US20090180975A1

Chemistry; metallurgy

Polynucleotide fragments of an infectious human endogenous retrovirus

#27 | 2009-05-21

US20090130129A1

Human necessities

Melanoma-associated endogenous retrovirus (MERV) derived peptide sequences and their therapeutic/diagnostic use

#28 | 2009-05-14

US20090123495A1

Human necessities

Immune Response Inducing Preparations

#29 | 2009-03-31

US10490920

Polynucleotide fragments of an infectious human endogenous retrovirus

#30 | 2009-02-26

US20090053264A1

Human necessities

Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals

#31 | 2008-01-10

US20080008717A1

Chemistry; metallurgy

Polynucleotide Fragments of an Infectious Human Endogenous Retrovirus

#32 | 2006-03-30

US20060069153A1

Human necessities

Dithiocarbamate antiviral agents and methods of using same

#33 | 2005-03-15

US10314569

Interferon inducing genetically engineered attenuated viruses

InventorID:

344849 ⎘